Evidence map›Paper›PMID 28164766›Full record

ReviewCurrent Alzheimer research2017

Biomarkers for Alzheimer's Disease Diagnosis.

Vasileios Mantzavinos, Athanasios Alexiou

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current Alzheimer research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 133 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
133citing papers in PubMed, 8 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

133 citing papers in PubMed, 8 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Analysis of the off-target interaction of amyloid PET tracers with human brain sulfotransferases.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Article
  11. Review
  12. miR-584-5p suppresses AβActa neurologica Belgica · 2026
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article

73 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Vasileios MantzavinosNovel Global Community Educational Foundational, Australia.
Athanasios AlexiouDepartment of Computer Science and Biomedical Informatics, University of Thessaly, 35100 Lamia, Greece.

Funding

Design And Development Of Experimental Therapeutics ((Systemic & Neurodegenerative Disorders and Alzheimer's Disease)ZIAAG000311 · NIA · NATIONAL INSTITUTE ON AGING · PI GREIG, NIGEL H. · 2009 to 2025
$16.0M
6 · The paper itself

Abstract

objectiveThe dramatic increase in the population with dementia expected in the next decades is accompanied by the establishment of novel and innovated methods that will offer accurate and efficient detection of the disease in its early stages. While Alzheimer's disease is the most common cause of dementia, by the time it is typically diagnosed, substantial neuronal loss and neuropathological lesions can damage many brain regions. The aim of this study is to investigate the main risk factors that affect and increase Alzheimer's disease progression over time even in cases with no significant memory impairment present. Several potential markers are discussed such as oxidative stress, metal ions, vascular disorders, protein dysfunctions and alterations in the mitochondrial populations.

conclusionA multiparametric model of Alzheimer's biomarkers is presented according to the latest classification of the disease.

Indexed as

Alzheimer DiseaseBiomarkersHumansBiomarkersAlzheimer's disease biomarkersmetal ionsmild cognitive impairmentmitochondrial dynamicsoxidative stressprotein dysfunctionsvascular disorders

Identifiers

PMID28164766
PMCPMC5684784

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.